BioNTech acquires Eufets
German biotech company BioNTech has acquired Eufets from Fresenius Biotech. Eufets is a GMP and GLP services specialist and under its new owner will retain all facilities, staff and contracts of the former company.
German biotech company BioNTech has acquired Eufets from Fresenius Biotech. Eufets is a GMP and GLP services specialist and under its new owner will retain all facilities, staff and contracts of the former company.
"The investment in Eufets is an excellent fit, endowing BioNTech with synergistic platforms and complementary expertise," said Dr Ugur Sahin, ceo of BioNTech.
The company said it would progress Eufets into a centre of excellence by developing and providing high-quality GMP/GLP services for recombinant vaccines, cell based therapies, gene- and immunotherapies.
Helmut Jeggle, chair of the supervisory board of BioNTech added: "The acquisition of Eufets is a logical step for our long-term strategy to build an excellent and competitive company for biopharmaceutical drug and biomarker development."
BioNTech is a "spin-off"-company of the Johannes Gutenberg University in Mainz, Germany.
